Oncocyte Corporation - Common Shares, No Par Value (OCX)
CUSIP: 68235C107
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Shares, No Par Value
- Shares outstanding
- 28,495,649
- Total 13F shares
- 47,078
- Share change
- -12,275
- Total reported value
- $112,046
- Price per share
- $2.38
- Number of holders
- 1
- Value change
- -$29,215
- Number of sells
- 1
Quarterly Holders Quick Answers
What is CUSIP 68235C107?
CUSIP 68235C107 identifies OCX - Oncocyte Corporation - Common Shares, No Par Value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 68235C107:
Top shareholders of OCX - Oncocyte Corporation - Common Shares, No Par Value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BROADWOOD CAPITAL INC |
13F
|
Company |
15%
|
4,929,066
|
$14,047,838 | — | 30 Sep 2024 | |
| Patrick W. Smith |
13D/G
|
— |
10%
|
1,773,903
|
$4,221,889 | $0 | 26 Dec 2024 | |
| AWM Investment Company, Inc. |
13F
|
Company |
3.4%
|
1,097,175
|
$3,126,949 | — | 30 Sep 2024 | |
| PURA VIDA INVESTMENTS, LLC |
3/4/5
13F
|
10%+ Owner · Company |
1.5%
from 13F
|
16,591,052
mixed-class rows
|
$3,044,309 | — | 14 Apr 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.76%
|
245,388
|
$699,356 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.32%
|
103,980
|
$296,400 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
0.25%
|
79,833
|
$227,525 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.22%
|
72,289
|
$206,024 | — | 30 Sep 2024 | |
| Defender Capital, LLC. |
13F
|
Company |
0.21%
|
59,353
|
$169,156 | — | 30 Sep 2024 | |
| John Peter Gutfreund |
3/4/5
|
Former Director |
—
mixed-class rows
|
760,000
mixed-class rows
|
$153,654 | — | 30 Jun 2023 | |
| Ronald Asbury Andrews |
3/4/5
|
Former CEO, Director |
—
mixed-class rows
|
633,212
mixed-class rows
|
$125,332 | — | 01 Dec 2022 | |
| FNY Investment Advisers, LLC |
13F
|
Company |
0.13%
|
42,896
|
$122,000 | — | 30 Sep 2024 | |
| Alfred D. Kingsley |
3/4/5
|
Director |
—
mixed-class rows
|
597,878
mixed-class rows
|
$109,143 | — | 23 Jun 2023 | |
| Gisela Paulsen |
3/4/5
|
Former President and COO |
—
class O/S missing
|
366,500
|
$78,761 | — | 16 Dec 2022 | |
| Li Yu |
3/4/5
|
VP Cntrllr/Prncpl Acctng Offcr |
—
mixed-class rows
|
41,872
mixed-class rows
|
$76,536 | — | 18 May 2022 | |
| STATE STREET CORP |
13F
|
Company |
0.06%
|
19,554
|
$55,729 | — | 30 Sep 2024 | |
| Ross Douglas T. |
3/4/5
|
Former CSO |
—
class O/S missing
|
234,114
|
$50,311 | — | 21 Dec 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.05%
|
17,346
|
$49,436 | — | 30 Sep 2024 | |
| Cavan M. Redmond |
3/4/5
|
Director |
—
class O/S missing
|
120,863
|
$25,973 | — | 24 Jun 2022 | |
| Mitchell S. Levine |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
174,580
mixed-class rows
|
$18,713 | — | 15 Mar 2022 | |
| Jennifer Levin Carter |
3/4/5
|
Director |
—
mixed-class rows
|
75,500
mixed-class rows
|
$6,554 | — | 15 Aug 2022 | |
| Melinda Griffith |
3/4/5
|
Director |
—
mixed-class rows
|
75,000
mixed-class rows
|
$6,447 | — | 15 Aug 2022 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
1,446
|
$4,121 | — | 30 Sep 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
1,080
|
$3,078 | — | 30 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
835
|
$2,380 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
412
|
$1,173 | — | 30 Sep 2024 | |
| Wilmington Savings Fund Society, FSB |
13F
|
Company |
0%
|
250
|
$713 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
154
|
$439 | — | 30 Sep 2024 | |
| Piscataqua Savings Bank |
13F
|
Company |
0%
|
25
|
$71 | — | 30 Sep 2024 | |
| Coppell Advisory Solutions LLC |
13F
|
Company |
0%
|
10
|
$29 | — | 30 Sep 2024 | |
| ALBION FINANCIAL GROUP /UT |
13F
|
Company |
0%
|
7
|
$20 | — | 30 Sep 2024 | |
| DANSKE BANK A/S |
13F
|
Company |
0%
|
1
|
$3 | — | 30 Sep 2024 | |
| Anish M. John |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
121,381
|
— | — | 24 Feb 2023 | |
| Padmavathi Sundar |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
87,500
|
— | — | 15 Mar 2022 |
Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q4 2024
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.